Summit Therapeutics Inc. (SMMT) stock
SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.67−1.15 (-9.73%)
Close on Nov 17, 2026Market cap $8.51BP/E –Yield –
Summit Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Summit Therapeutics's enterprise value was $12.51B on Nov 11, 2026, against $13.08B a year earlier. Over the last 5 years it ranged from $20.67M to $19.19B, with a median of $6.04B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $12.51B | -2.2% |
| 2025 | Dec 31, 2025 | $12.78B | +0.9% |
| 2024 | Dec 31, 2024 | $12.67B | +680.7% |
| 2023 | Dec 29, 2023 | $1.62B | +121.1% |
| 2022 | Dec 30, 2022 | $733.64M | +302.3% |
| 2021 | Dec 31, 2021 | $182.37M | +298.8% |
| 2020 | Dec 31, 2020 | $45.73M | – |
| 2019 | Dec 31, 2019 | -$7.68M | – |
| 2018 | Dec 31, 2018 | -$13.45M | -109.9% |
| 2017 | Dec 29, 2017 | $136.39M | +34.8% |
| 2016 | Dec 30, 2016 | $101.18M | – |
See a number that looks wrong?